These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3294284)

  • 1. Dextro-amphetamine diminishes negative symptoms in schizophrenia.
    van Kammen DP; Boronow JJ
    Int Clin Psychopharmacol; 1988 Apr; 3(2):111-21. PubMed ID: 3294284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
    Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Dalton L; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):261-6. PubMed ID: 7065839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
    van Kammen DP; Bunney WE; Docherty JP; Marder SR; Ebert MH; Rosenblatt JE; Rayner JN
    Am J Psychiatry; 1982 Aug; 139(8):991-7. PubMed ID: 7091448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
    van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pimozide and chlorpromazine in acute schizophrenia.
    Pecknold JC; McClure DJ; Allan T; Wrzesinski L
    Can J Psychiatry; 1982 Apr; 27(3):208-12. PubMed ID: 7046898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
    van Kammen DP; Docherty JP; Bunney WE
    Biol Psychiatry; 1982 Feb; 17(2):233-42. PubMed ID: 7074181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimozide versus chlorpromazine in chronic schizophrenia: a 52 week double-blind study of maintenance therapy.
    Wilson LG; Roberts RW; Gerber CJ; Johnson MH
    J Clin Psychiatry; 1982 Feb; 43(2):62-5. PubMed ID: 7035441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
    Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
    J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dextro-propranolol and depressive symptoms in a schizophrenic population.
    Manchanda R
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):625-32. PubMed ID: 3321153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimozide in acute schizophrenia: a pilot study.
    Garton D; Silverstone T
    Curr Med Res Opin; 1979; 5(10):799-806. PubMed ID: 373996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of imipramine antidepressant response by a one-day dextro-amphetamine trial.
    van Kammen DP; Murphy DL
    Am J Psychiatry; 1978 Oct; 135(10):1179-84. PubMed ID: 358845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group.
    McCreadie RG; Wiles D; Grant S; Crockett GT; Mahmood Z; Livingston MG; Watt JA; Greene JG; Kershaw PW; Todd NA
    Acta Psychiatr Scand; 1989 Dec; 80(6):597-602. PubMed ID: 2694767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics.
    Cheadle AJ; Freeman HL
    Curr Med Res Opin; 1979; 6(1):35-43. PubMed ID: 378556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia.
    Pandurangi AK; Goldberg SC; Brink DD; Hill MH; Gulati AN; Hamer RM
    Biol Psychiatry; 1989 Jan; 25(2):207-14. PubMed ID: 2649157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial improvement in negative schizophrenic symptoms after amphetamine.
    Angrist B; Peselow E; Rubinstein M; Corwin J; Rotrosen J
    Psychopharmacology (Berl); 1982; 78(2):128-30. PubMed ID: 6817367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
    Gross MD
    Dis Nerv Syst; 1976 Jan; 37(1):14-6. PubMed ID: 1106966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimozide in the treatment of newly admitted schizophrenic patients.
    Chouinard G; Annable L
    Psychopharmacology (Berl); 1982; 76(1):13-9. PubMed ID: 6805002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment.
    van Kammen DP; Docherty JP; Marder SR; Siris SG; Bunney WE
    Life Sci; 1978 Oct; 23(14):1487-92. PubMed ID: 362103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.